Craig Hallum initiated coverage on BioHarvest Sciences with a new price target
$BHST
Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $15.00 | Buy | Craig Hallum |
| 12/18/2024 | $12.00 | Buy | Maxim Group |
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter
Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 MillionCDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based SweetenersRehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024.Fourth Quarter 2024 & Subsequent Operational HighlightsAll figures stated in this news release are in U.S.
Rehovot, Israel--(Newsfile Corp. - March 17, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, March 31, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Monday, March 31, 2025, to discuss the Company's fourth quarter and full year 2024 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the
Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter
Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 MillionCDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based SweetenersRehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024.Fourth Quarter 2024 & Subsequent Operational HighlightsAll figures stated in this news release are in U.S.
Rehovot, Israel--(Newsfile Corp. - March 17, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, March 31, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Monday, March 31, 2025, to discuss the Company's fourth quarter and full year 2024 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the
Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00
Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00
Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division